MedTrace Logo

Role of a Mitochondrial Receptor in Blood Sugar Regulation

NCT07682233 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-07-02

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether a single dose of XBD173, a medicine that binds to a protein called the 18 kiloDalton Translocator Protein (TSPO), affects how the body processes glucose in healthy volunteers aged 18 to 75 years.

The main questions it aims to answer are:

* Does a single dose of XBD173 change fasting blood glucose levels compared with placebo?
* Does a single dose of XBD173 change blood glucose levels after participants drink a glucose solution compared with placebo?

Researchers will compare XBD173 with a placebo, which does not contain the active medicine, to see whether activating TSPO affects glucose metabolism in the fasting state and after a glucose drink.

Participants will:

* Attend a screening visit to confirm eligibility, including a medical history, physical examination and blood tests.
* Attend four study visits after fasting overnight: two visits involving a glucose drink and two visits without a glucose drink.
* Receive a single oral dose of XBD173 at some visits and placebo at other visits. The order will be randomised, and neither participants nor the study team conducting the assessments will know which treatment is given during each visit.
* Have repeated blood samples taken through a cannula to measure glucose, insulin and other markers related to metabolism and inflammation.
* Have resting energy use measured by breathing under a transparent canopy connected to a standard metabolic measurement device.
* Have blood pressure, heart rate, height and weight measured.
* Undergo measurement of blood vessel function using a cuff.

Conditions

  • Heathly Volunteers

Interventions

DRUG

XBD173

90mg XBD173 oral dose

DRUG

Placebo

Participants will receive a placebo drug, identical in appearance to XBD173.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-27
Primary Completion
2028-09-01
Completion
2028-09-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07682233 on ClinicalTrials.gov